Novo Nordisk Cuts Costs on Two Fronts as Pipeline Timelines Stretch

Novo Nordisk prepares for steep US price cuts in 2027, squeezes suppliers for discounts, and ramps up India production to defend GLP-1 market share from Eli Lilly, despite pipeline setbacks with CagriSema.

The Danish drugmaker is pulling every lever to defend its GLP-1 franchise. It is squeezing suppliers for discounts while simultaneously ramping up production capacity through a new partner in India — moves that come as the company prepares for a steep price cut in the United States next year and contends with a mixed pipeline outlook.

Novo Nordisk confirmed it has sent letters to suppliers demanding they reduce prices in order to keep their contracts "commercially viable." The request, which some suppliers interpret as a heavy-handed warning, aims to shore up margins ahead of a brutal price-adjustment period. Starting in January 2027, the list price of Ozempic will drop 35% and Wegovy will be cut by half under U.S. reimbursement rules. The company is also adding production firepower: Shantha Biologics will now fill syringes at its U.S.-certified plant in Hyderabad, India, a move that adds much-needed capacity for the booming demand for injectable weight-loss drugs.

The shift comes as Novo Nordisk plays catch-up with arch-rival Eli Lilly. According to first-quarter 2026 data, Novo holds roughly 40% of the GLP-1 market versus Lilly's 60%. The new Indian supply line and the supplier squeeze are both aimed at preserving margins while the company fights for market share.

On the demand side, a fresh Medicare program that started in early July is widening access. Eligible patients now pay only $50 per month for Wegovy. Separately, Amazon has begun delivering oral versions of the drug the same day in select regions, lowering the barrier for new patients. Since the U.S. launch of the Wegovy tablet, Novo has recorded roughly 3 million prescriptions.

The stock has responded warmly to the strategy. Shares closed Thursday at €43.92, up 2.25% on the day and 19.22% over the past 30 days. The rally has pushed the 14-day relative strength index to 75.5 — deeply into overbought territory. The stock now trades 7.57% above its 200-day moving average and 14.05% above its 50-day average. But it remains 25.86% lower than a year ago and 28.24% below the 52-week high of €61.20 set in July 2025.

The technical exuberance masks a pipeline that has hit speed bumps. The market's next major catalyst is CagriSema, a combination therapy Novo hopes will re-establish a growth narrative. The company expects the FDA to review its approval application sometime in 2026. Yet the open-label Phase 3 trial REDEFINE 4, which compared once-weekly CagriSema at a 15-mg dose directly against Lilly's tirzepatid, failed to meet its primary endpoint of non-inferiority in weight loss after 84 weeks. Definitive results from REDEFINE 11, which tests the full potential of CagriSema in obesity, will not come until the first half of 2027. And a Phase 3 study of a higher dose will not start until the second half of 2026. Meanwhile, Novo is also generating fresh data on Ozempic, Wegovy, and the early-stage candidate Zenagamtide, but those readouts are unlikely to shift the needle near-term.

Analysts see a fair-value range around €38.50 based on fundamental models, suggesting the current price leaves little room for error. The stock's 30-day annualized volatility of 31.17% underscores how fragile sentiment remains. If the supplier squeeze does not translate into visible margin protection, or if competitive pressure from Eli Lilly intensifies, a pullback toward that level looks plausible.

Two dates stand out in the months ahead: the FDA's decision on the CagriSema application, expected at some point in 2026, and the start of the higher-dose CagriSema study in the second half of the year. Both events have the power to rewrite the stock's narrative — long before the full REDEFINE 11 dataset arrives in early 2027. Until then, Novo Nordisk is fighting a two-front war: one against competitors for market share, and another against its own cost base to keep the profits flowing.